Royalty Pharma (RPRX) Net Cash Flow Growth (5y) (2024 - 2026)
Royalty Pharma (RPRX) Net Cash Flow Growth (5y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | Royalty Pharma | 25.73 Bn | 25.12 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.96% |
| Dec 31, 2025 | 10.06% |
| Sep 30, 2025 | 19.13% |
| Jun 30, 2025 | -17.61% |
| Mar 31, 2025 | -8.83% |
| Dec 31, 2024 | -16.67% |
| Sep 30, 2024 | -11.30% |